News from NORD

The National Center for Advancing Translational Sciences is seeking applications for pre-clinical research projects based on repurposing existing drugs or biologics through a new funding opportunity. Letters of intent are due by Dec. 13, 2015.

The National Center for Advancing Translational Sciences is seeking applications for pre-clinical research projects based on repurposing existing drugs or biologics through a new funding opportunity. Letters of intent are due by Dec. 13, 2015.

The National Center for Advancing Translational Sciences is seeking applications for pre-clinical research projects based on repurposing existing drugs or biologics through a new funding opportunity. Letters of intent are due by Dec. 13, 2015.

The Sturge-Weber Foundation has announced the formation of the SWF International Research Network, an initiative to support international collaboration among medical experts and scientific researchers in the treatment of Sturge-Weber syndrome, port wine birthmarks, and Klippel-Trenaunay syndrome. 

The Sturge-Weber Foundation has announced the formation of the SWF International Research Network, an initiative to support international collaboration among medical experts and scientific researchers in the treatment of Sturge-Weber syndrome, port wine birthmarks, and Klippel-Trenaunay syndrome. 

The Sturge-Weber Foundation has announced the formation of the SWF International Research Network, an initiative to support international collaboration among medical experts and scientific researchers in the treatment of Sturge-Weber syndrome, port wine birthmarks, and Klippel-Trenaunay syndrome. 

CurePSP and the Tau Consortium, leading foundations fighting neurodegenerative disease, have brought together a team of prominent investigators who will launch the definitive study of the gene variants involved in progressive supranuclear palsy (PSP). PSP is a deadly brain disorder that afflicts about 20,000 people in the US and is a leading target for researchers seeking to understand all neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.

CurePSP and the Tau Consortium, leading foundations fighting neurodegenerative disease, have brought together a team of prominent investigators who will launch the definitive study of the gene variants involved in progressive supranuclear palsy (PSP). PSP is a deadly brain disorder that afflicts about 20,000 people in the US and is a leading target for researchers seeking to understand all neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.

CurePSP and the Tau Consortium, leading foundations fighting neurodegenerative disease, have brought together a team of prominent investigators who will launch the definitive study of the gene variants involved in progressive supranuclear palsy (PSP). PSP is a deadly brain disorder that afflicts about 20,000 people in the US and is a leading target for researchers seeking to understand all neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.

New international consensus diagnostic criteria have recently been published for NMO, an uncommon disease syndrome of the central nervous system that affects the optic nerves and spinal cord. Affected individuals develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control.

The 2015 consensus diagnostic criteria for NMO and NMO spectrum disorders (NMO/SD) apply the latest scientific and medical insights into adult and pediatric disease, imaging, laboratory tests, and potential relationships of NMO/SD to other autoimmune diseases. These new criteria are anticipated to improve diagnostic accuracy of NMO/SD and other autoimmune diseases and speed appropriate therapies.

New international consensus diagnostic criteria have recently been published for NMO, an uncommon disease syndrome of the central nervous system that affects the optic nerves and spinal cord. Affected individuals develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control.

The 2015 consensus diagnostic criteria for NMO and NMO spectrum disorders (NMO/SD) apply the latest scientific and medical insights into adult and pediatric disease, imaging, laboratory tests, and potential relationships of NMO/SD to other autoimmune diseases. These new criteria are anticipated to improve diagnostic accuracy of NMO/SD and other autoimmune diseases and speed appropriate therapies.

New international consensus diagnostic criteria have recently been published for NMO, an uncommon disease syndrome of the central nervous system that affects the optic nerves and spinal cord. Affected individuals develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control.

The 2015 consensus diagnostic criteria for NMO and NMO spectrum disorders (NMO/SD) apply the latest scientific and medical insights into adult and pediatric disease, imaging, laboratory tests, and potential relationships of NMO/SD to other autoimmune diseases. These new criteria are anticipated to improve diagnostic accuracy of NMO/SD and other autoimmune diseases and speed appropriate therapies.

The Institute of Medicine (IOM) has published a report in which it cites diagnostic errors as a common and harmful patient safety problem. The IOM report outlines eight goals and provides specific recommendations to reduce diagnostic error and improve diagnosis.

The Institute of Medicine (IOM) has published a report in which it cites diagnostic errors as a common and harmful patient safety problem. The IOM report outlines eight goals and provides specific recommendations to reduce diagnostic error and improve diagnosis.

The Institute of Medicine (IOM) has published a report in which it cites diagnostic errors as a common and harmful patient safety problem. The IOM report outlines eight goals and provides specific recommendations to reduce diagnostic error and improve diagnosis.

The National Center for Advancing Translational Sciences is seeking applications for pre-clinical research projects based on repurposing existing drugs or biologics through a new funding opportunity. Letters of intent are due by Dec. 13, 2015.

The National Center for Advancing Translational Sciences is seeking applications for pre-clinical research projects based on repurposing existing drugs or biologics through a new funding opportunity. Letters of intent are due by Dec. 13, 2015.

The National Center for Advancing Translational Sciences is seeking applications for pre-clinical research projects based on repurposing existing drugs or biologics through a new funding opportunity. Letters of intent are due by Dec. 13, 2015.

Learning sessions have been scheduled for Nov. 18 to discuss how volunteers are protected in research and possible changes to the federal regulations. Individuals may participate in person or via live webinar.

Learning sessions have been scheduled for Nov. 18 to discuss how volunteers are protected in research and possible changes to the federal regulations. Individuals may participate in person or via live webinar.

Learning sessions have been scheduled for Nov. 18 to discuss how volunteers are protected in research and possible changes to the federal regulations. Individuals may participate in person or via live webinar.

The Office of Orphan Products Development (OOPD) at the Food and Drug Administration (FDA) has posted information for those interested in applying for orphan product development grants. These are grants to support the clinical development of products for use in rare diseases or conditions for which no current therapy exists or when the product being developed will be superior to existing treatments.

The Office of Orphan Products Development (OOPD) at the Food and Drug Administration (FDA) has posted information for those interested in applying for orphan product development grants. These are grants to support the clinical development of products for use in rare diseases or conditions for which no current therapy exists or when the product being developed will be superior to existing treatments.

The Office of Orphan Products Development (OOPD) at the Food and Drug Administration (FDA) has posted information for those interested in applying for orphan product development grants. These are grants to support the clinical development of products for use in rare diseases or conditions for which no current therapy exists or when the product being developed will be superior to existing treatments.

The National Center for Advancing Translational Sciences is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps and Therapeutics for Rare and Neglected Diseases program scientists.

The National Center for Advancing Translational Sciences is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps and Therapeutics for Rare and Neglected Diseases program scientists.

The National Center for Advancing Translational Sciences is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps and Therapeutics for Rare and Neglected Diseases program scientists.

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is collecting stakeholder input on the scientific and operational opportunities, challenges, and research needs in translational science. The information will help determine the Center’s strategic priorities and inform the development of a five-year strategic plan. The deadline to submit input is January 8, 2016.

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is collecting stakeholder input on the scientific and operational opportunities, challenges, and research needs in translational science. The information will help determine the Center’s strategic priorities and inform the development of a five-year strategic plan. The deadline to submit input is January 8, 2016.

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is collecting stakeholder input on the scientific and operational opportunities, challenges, and research needs in translational science. The information will help determine the Center’s strategic priorities and inform the development of a five-year strategic plan. The deadline to submit input is January 8, 2016.